Holen Sie sich die Stockscreener-App
4.71
2.08%
-0.10
Handel nachbörslich:
4.60
-0.11
-2.34%
Coya Therapeutics Inc Aktie (COYA) Neueste Nachrichten
COYA | Coya Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
Coya Therapeutics secures FDA fast track status for COYA 302 - Yahoo Finance
Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Palisade Bio (PALI) - The Globe and Mail
Lake Street Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $17 - Moomoo
8-K: Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Updatemoomoo - Moomoo
H.C. Wainwright Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Chardan Capital Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $14 - Moomoo
FDA puts injection therapy COYA 302 on fast track for treating ALS - ALS News Today
[ARS] Coya Therapeutics, Inc. SEC Filing - Stock Titan
Coya Therapeutics (COYA) 2026 proxy outlines director elections and auditor ratification - Stock Titan
Coya Therapeutics 1Q Research and Development Expenses $4.1 M >COYA - Moomoo
FDA Fast Track Designation Boosts ALS Treatment Outlook; Analyst Sees More Than 250% Upside Potential - Streetwise Reports
Coya Therapeutics Announces $30 Million At-the-Market Offering Agreement with Leerink Partners - Minichart
Coya Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Coya Therapeutics, Inc. Q1 2026 10-Q Filing: Financial Statements, Market Risks, and Legal Disclosures - Minichart
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of - pharmiweb.com
Coya Therapeutics Establishes $30 Million ATM Equity Program - TipRanks
Coya Therapeutics entered into sales agreement, may offer and sell from time to time shares of co's common stock for up to $30 million - marketscreener.com
Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million - TradingView
Coya Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Coya Therapeutics Updates Q1 Results, COYA 302 Progress - TipRanks
Coya Therapeutics (COYA) launches $30,000,000 at-the-market stock offering - Stock Titan
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - BioSpace
Coya Therapeutics (COYA) launches $30M at‑the‑market equity program with Leerink - Stock Titan
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - BioSpace
Coya Therapeutics receives FDA fast track for ALS treatment By Investing.com - Investing.com Australia
Coya Therapeutics Reports Q1 2026 Financial Results, Highlights ALS and FTD Drug Progress and FDA Fast Track Designation - Minichart
Coya Therapeutics receives FDA fast track for ALS treatment - Investing.com
Coya Therapeutics, Inc. 1Q 2026: Revenue $0.25M, EPS $(0.32) — 10-Q Summary - TradingView
Coya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Coya Therapeutics (NASDAQ: COYA) posts Q1 loss as COYA 302 wins FDA Fast Track - Stock Titan
Fast Track lifts Coya Therapeutics (NASDAQ: COYA) Q1 2026 biotech update - Stock Titan
TradingKey - TradingKey
Coya Therapeutics Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Why Coya (COYA) is still under the radar (Touches Low) 2026-05-07Oversold Bounce - Newser
Coya Therapeutics (COYA) Expected to Announce Earnings on Tuesday - MarketBeat
ALS Researchers Use Stratification, Diverse Endpoints To Address Heterogeneity - Clinical Leader
Coya Therapeutics raises $11.1M in private placement led by Dr. Reddy's - MSN
Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), ClearPoint Neuro (CLPT) and CG Oncology, Inc. (CGON) - The Globe and Mail
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Coya Therapeutics (NASDAQ:COYA) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Mark H Pavao Net Worth (2026) - GuruFocus
COYA Options Volatility — NASDAQ:COYA - TradingView
COYA Options Chain — NASDAQ:COYA - TradingView
Is Coya (COYA) Stock Safe to Buy Now | COYA Q4 Earnings: Misses Estimates by $0.06Expert Breakout Alerts - Newser
COYA PE Ratio & Valuation, Is COYA Overvalued - Intellectia AI
COYA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Volume Report: Is Coya Therapeutics Inc impacted by rising ratesTrade Analysis Report & High Accuracy Trade Alerts - baoquankhu1.vn
Coya Therapeutics Is Maintained at Buy by D. Boral Capital - Moomoo
Coya Therapeutics' (COYA) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Market Review: Is Coya Therapeutics Inc benefiting from innovation trends2026 Catalysts & Accurate Entry/Exit Alerts - baoquankhu1.vn
Coya Therapeutics (COYA) director receives 10,000 stock options at $4.53 - Stock Titan
New Coya Therapeutics (COYA) director Mark H. Pavao files initial Form 3 - Stock Titan
Stop Loss: Will Coya Therapeutics Inc outperform its industry peers2026 Bull vs Bear & Technical Pattern Based Signals - baoquankhu1.vn
Market Leaders: How do insiders feel about Coya Therapeutics Inc2026 Earnings Impact & Free High Return Stock Watch Alerts - baoquankhu1.vn
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS - Business Wire
User - The Chronicle-Journal
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):